Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 10/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | PPARA | Q07869 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.36 |
| ▸ | RXRB | P28702 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6481703 | 0.88 | PPARD (0.58) | PPARDPKMPPARGPPARATHRB | |
| SCHEMBL6473160 | 0.88 | PPARD (0.71) | PPARDPKMPPARGPPARAGAA | |
| SCHEMBL6473989 | 0.88 | PPARD (0.65) | PPARDPKMPPARGPPARAALDH1A1 | |
| SCHEMBL6481912 | 0.88 | PPARD (0.61) | PPARDPPARGPPARAGAAALDH1A1 | |
| SCHEMBL6529994 | 0.87 | PPARD (0.64) | PPARDPPARGPPARAGAATHRB | |
| SCHEMBL6474472 | 0.86 | PPARD (0.79) | PPARDGAAALDH1A1TSHRNFKB1 | |
| SCHEMBL6473770 | 0.85 | PPARD (0.61) | PPARDPKMPPARGPPARAALDH1A1 | |
| SCHEMBL6474916 | 0.82 | PPARD (0.57) | PPARDPKMPPARGPPARA | |
| SCHEMBL6475700 | 0.82 | PPARD (0.57) | PPARDPKMPPARGPPARARXRA | |
| SCHEMBL6480547 | 0.81 | PPARD (0.56) | PPARDPPARGPPARAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | claimed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | claimed |
| US-6869967-B2 | Peroxisome proliferator-activated receptor (PPAR) active vinyl carboxylic acid derivatives | NOVO NORDISK A/S (DK) | 2005-03-22 | — | — | US | disclosed |
| US-20030139473-A1 | Novel compounds, their preparation and use | VTVX HOLDINGS II LLC | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139473-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | PPARD 2/4885PKM 793/4885PPARG 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.